NOURIN
LIVE

Serial Number

88768088

Owner

Nour Heart, Inc.

Attorney

Shuo Che Chou

First Use Date

Oct 19, 2020

Filing Date

Jan 21, 2020

Add to watchlist:

No watchlists yet
View on USPTO

NOURIN Trademark

Serial Number: 88768088 • Registration: 6274061

NOURIN is a trademark filed by Nour Heart, Inc. on January 21, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Nour Heart, Inc. (2 trademarks)

Vienna, VA 22180

Entity Type: 03

Trademark Details

Filing Date

January 21, 2020

Registration Date

February 16, 2021

First Use Anywhere

October 19, 2020

First Use in Commerce

October 19, 2020

Published for Opposition

June 9, 2020

Goods & Services

protein arrays for research purposes; gene-based RNA molecular network being RNA sequences for research purposes; protein arrays for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for research purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for research use; diagnostic biomarker reagents for research purposes; protein arrays of biomarker reagents for research purposes; gene-based RNA molecular network biomarker reagents for research purposes; protein arrays and gene-based RNA molecular network biomarker reagents for research purposes; tissue-derived diagnostic biomarker reagents for research purposes; cardiac-derived diagnostic biomarker reagents for research purposes

protein arrays for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for medical diagnosis purposes; protein arrays for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for medical use; diagnostic biomarker reagents for medical purposes; protein arrays of biomarker reagents for medical diagnosis purposes; gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; protein arrays and gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; tissue-derived diagnostic biomarker reagents for medical purposes; cardiac-derived diagnostic biomarker reagents for medical purposes

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Feb 16, 2026 REM1
REGISTERED-PRINCIPAL REGISTER
Feb 16, 2021 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jan 15, 2021 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jan 14, 2021 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jan 14, 2021 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 13, 2021 AITU
USE AMENDMENT FILED
Dec 22, 2020 IUAF
TEAS STATEMENT OF USE RECEIVED
Dec 22, 2020 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 4, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 9, 2020 NPUB
PUBLISHED FOR OPPOSITION
Jun 9, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 20, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 5, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 25, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 24, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 24, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 13, 2020 GNRN
NON-FINAL ACTION E-MAILED
Apr 13, 2020 GNRT
NON-FINAL ACTION WRITTEN
Apr 13, 2020 CNRT
ASSIGNED TO EXAMINER
Apr 8, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 25, 2020 NWOS
NEW APPLICATION ENTERED
Jan 24, 2020 NWAP